What this Trial Is About

Researchers are evaluating the effects of autologous platelet-rich plasma (PRP) intra ovarian infusion on restoring ovarian function and promoting follicle development in menopausal women aged 45 to 55. This study is a triple-blind randomized controlled trial focusing on women experiencing menopause with amenorrhea for at least 12 months. PRP, derived from the patient's own blood and enriched with growth factors, has been used in other medical fields for tissue healing, but its role in ovarian rejuvenation and endometrial regeneration is still under investigation. Participants will receive either autologous PRP intra ovarian infusion or autologous platelet-free plasma (PFP) intra ovarian infusion as a comparison. The procedures involve infusing these biological preparations directly into the ovaries. Prior to recruitment, participants must have stopped any complementary or hormone treatments for at least three months. The trial is conducted in phases 2 and 3 to assess the treatment's effectiveness and safety. During the study, researchers will monitor the restoration of the menstrual cycle over three months and measure serum follicle-stimulating hormone (FSH) levels monthly during the follow-up period. Participants will be assessed for ovarian function and hormonal profiles. The study requires compliance with all study procedures and careful monitoring of reproductive health and hormone levels throughout the trial.

Autologous PRP Intra Ovarian Infusion to Restore Ovarian Function in Menopausal Women